CN113105389A - 一种阿立哌唑药物共晶及其制备方法 - Google Patents
一种阿立哌唑药物共晶及其制备方法 Download PDFInfo
- Publication number
- CN113105389A CN113105389A CN202110412265.2A CN202110412265A CN113105389A CN 113105389 A CN113105389 A CN 113105389A CN 202110412265 A CN202110412265 A CN 202110412265A CN 113105389 A CN113105389 A CN 113105389A
- Authority
- CN
- China
- Prior art keywords
- degrees
- aripiprazole
- resveratrol
- crystal
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 229960004372 aripiprazole Drugs 0.000 title claims abstract description 87
- 239000013078 crystal Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 52
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 51
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 51
- 229940016667 resveratrol Drugs 0.000 claims abstract description 51
- 230000005496 eutectics Effects 0.000 claims abstract description 25
- 238000000227 grinding Methods 0.000 claims abstract description 17
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 6
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 6
- 238000001291 vacuum drying Methods 0.000 claims abstract description 5
- -1 alkyl nitrile Chemical class 0.000 claims abstract description 4
- 150000002576 ketones Chemical class 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 239000008363 phosphate buffer Substances 0.000 abstract description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 16
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BUWPZNOVIHAWHW-UHFFFAOYSA-N 2,3-dihydro-1h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CCNC2=C1 BUWPZNOVIHAWHW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940025916 aripiprazole injection Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
- C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间点 | XRPD表征 |
1月 | 共晶 |
2月 | 共晶 |
4月 | 共晶 |
6月 | 共晶 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110412265.2A CN113105389B (zh) | 2021-04-16 | 2021-04-16 | 一种阿立哌唑药物共晶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110412265.2A CN113105389B (zh) | 2021-04-16 | 2021-04-16 | 一种阿立哌唑药物共晶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113105389A true CN113105389A (zh) | 2021-07-13 |
CN113105389B CN113105389B (zh) | 2022-04-08 |
Family
ID=76718025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110412265.2A Active CN113105389B (zh) | 2021-04-16 | 2021-04-16 | 一种阿立哌唑药物共晶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113105389B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114149426A (zh) * | 2021-12-13 | 2022-03-08 | 江苏海洋大学 | 帕博西尼药物共晶及其制备方法 |
CN114344303A (zh) * | 2022-01-13 | 2022-04-15 | 江苏海洋大学 | 一种新型精神药物固体分散体及制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107141253A (zh) * | 2016-03-01 | 2017-09-08 | 天津市汉康医药生物技术有限公司 | 一种阿立哌唑倍半水合物化合物 |
CN111454207A (zh) * | 2014-08-25 | 2020-07-28 | 奥克梅斯制药爱尔兰有限公司 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
CN111909086A (zh) * | 2020-05-05 | 2020-11-10 | 天津大学 | 阿立哌唑-乙酰水杨酸盐及制备方法 |
-
2021
- 2021-04-16 CN CN202110412265.2A patent/CN113105389B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111454207A (zh) * | 2014-08-25 | 2020-07-28 | 奥克梅斯制药爱尔兰有限公司 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
CN107141253A (zh) * | 2016-03-01 | 2017-09-08 | 天津市汉康医药生物技术有限公司 | 一种阿立哌唑倍半水合物化合物 |
CN111909086A (zh) * | 2020-05-05 | 2020-11-10 | 天津大学 | 阿立哌唑-乙酰水杨酸盐及制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114149426A (zh) * | 2021-12-13 | 2022-03-08 | 江苏海洋大学 | 帕博西尼药物共晶及其制备方法 |
CN114344303A (zh) * | 2022-01-13 | 2022-04-15 | 江苏海洋大学 | 一种新型精神药物固体分散体及制备方法和应用 |
CN114344303B (zh) * | 2022-01-13 | 2023-05-09 | 江苏海洋大学 | 一种新型精神药物固体分散体及制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113105389B (zh) | 2022-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6720280B2 (ja) | 新規アベキシノスタット塩、関連結晶形態、それらの調製方法およびそれらを含有する医薬組成物 | |
CN113105389B (zh) | 一种阿立哌唑药物共晶及其制备方法 | |
WO2016165650A1 (zh) | 奥拉帕尼与尿素的共晶及其制备方法 | |
US10208065B2 (en) | Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
CN110922403A (zh) | 阿哌沙班与羧酸形成的共晶及其制备方法 | |
EP3263573B1 (en) | Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal | |
WO2018117267A1 (ja) | 置換ピペリジン化合物の塩 | |
JP6676626B2 (ja) | アシルチオウレア化合物のメシル酸塩の結晶及びその製造方法 | |
KR101721288B1 (ko) | 티에노피리미딘 유도체의 결정 | |
CN111233762B (zh) | 一种乐伐替尼与对羟基苯甲酸共晶及其制备方法 | |
WO2014187229A1 (zh) | 阿戈美拉汀晶型i的制备方法 | |
CN109438372B (zh) | 一种甲基吡嗪衍生物甲醇合物 | |
CN108570045B (zh) | 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物 | |
WO2020224208A1 (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
CN110218209B (zh) | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 | |
WO2018137670A1 (zh) | 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途 | |
WO2006026927A1 (fr) | Nouveau polymorphe de monohydrate de mesylate de dolasetron et sa preparation | |
JPWO2004020433A1 (ja) | 新規結晶 | |
WO2022199708A1 (zh) | 卢美哌隆药用盐、制备方法、含其的药物组合物及应用 | |
WO2024056079A1 (zh) | 内匹司他酸加成盐的多晶型及其制备方法和用途 | |
WO2023098612A1 (zh) | 二甲基亚磺酰亚胺衍生物的盐型及晶型 | |
CN109096218B (zh) | 盐酸奥达特罗晶型a及其制备方法 | |
TWI768595B (zh) | 用於製備超純曲前列環素之高效結晶方法及由其製得之晶體 | |
CN112851643B (zh) | 嘧啶苯甲酰胺化合物的盐酸盐及其用途 | |
WO2022009815A1 (ja) | オクタヒドロチエノキノリン化合物のコハク酸塩及びその結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230821 Address after: Building 501, Zhenguan International, No. 7 Jinghai Road, Yizhuang Town, Daxing District, Beijing, 100023 Patentee after: Chang Yan Address before: Room 101, Building 2, No. 95 Daguan Middle Road, Tianhe District, Guangzhou City, Guangdong Province, 510000 Patentee before: Guangzhou Zhongtian Technology Consulting Co.,Ltd. Effective date of registration: 20230821 Address after: Room 101, Building 2, No. 95 Daguan Middle Road, Tianhe District, Guangzhou City, Guangdong Province, 510000 Patentee after: Guangzhou Zhongtian Technology Consulting Co.,Ltd. Address before: No.59 Cangwu Road, Xinpu District, Lianyungang City, Jiangsu Province 222000 Patentee before: Jiangsu Ocean University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230904 Address after: Room 202, Inspection Warehouse Office Area, No. 6262 Australia Road, Tianjin Free Trade Pilot Zone (Dongjiang Bonded Port Area), Binhai New Area, Tianjin, 300450 (Tianjin Dongjiang Business Secretary Service Co., Ltd. Free Trade Branch Trusteeship No. 4895) Patentee after: Kunrui (Tianjin) Enterprise Management Partnership (L.P.) Address before: Building 501, Zhenguan International, No. 7 Jinghai Road, Yizhuang Town, Daxing District, Beijing, 100023 Patentee before: Chang Yan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231023 Address after: No. 40, Liujia Street, Liujia Town, Jinchengjiang District, Hechi City, Guangxi Zhuang Autonomous Region, 547000 Patentee after: Guangxi Kunyu Pharmaceutical Co.,Ltd. Address before: Room 202, Inspection Warehouse Office Area, No. 6262 Australia Road, Tianjin Free Trade Pilot Zone (Dongjiang Bonded Port Area), Binhai New Area, Tianjin, 300450 (Tianjin Dongjiang Business Secretary Service Co., Ltd. Free Trade Branch Trusteeship No. 4895) Patentee before: Kunrui (Tianjin) Enterprise Management Partnership (L.P.) |